Published on
Last updated on
NMPA Solicits Public Opinions on the Reclassification of IVD Reagents
On 24.04.2020, the NMPA (National Medical Products Administration) announced a draft proposal to reclassify some of the IVD reagents in the 6840 Classified Subdirectory (2013 Version), and solicited public opinions until 10.05.2020.
In addition, the draft proposal reclassifies some other IVD reagents including test kits for tumours and cancer diseases.
By Jacky Li. Contact Cisema to learn more.
Related News
Malaysia Introduces New e-IFU & Digital Labelling Guidance for Medical Devices
Malaysia’s MDA publishes the 7th edition of guidance on medical device labelling, with new e-labelling, e-IFU, and accessibility requirements
Vietnam Authorities Step Up Cosmetic Recalls as Enforcement Tightens
Vietnam’s Drug Administration (DAV) is stepping up cosmetic product recalls as post-market surveillance tightens.
BPOM Clarifies Indonesia–US Trade Agreement Impact on Pharmaceutical Regulation
BPOM confirms pharmaceutical authorization, GMP oversight, and regulatory authority remain unchanged under the Indonesia–US trade agreement.